Trustmark National Bank Trust Department’s AbbVie ABBV Stock Holding History

Trustmark National Bank Trust Department’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.42M	Buy	38,707 +133	+0.3%	+$29.5K	0.54%	41
2025 Q4	$8.81M	Sell	38,574 -547	-1%	-$125K	0.56%	39
2025 Q3	$9.06M	Sell	39,121 -248	-0.6%	-$50.5K	0.59%	36
2025 Q2	$7.31M	Buy	39,369 +204	+0.5%	+$37.9K	0.5%	40
2025 Q1	$8.21M	Sell	39,165 -544	-1%	-$106K	0.61%	34
2024 Q4	$7.06M	Sell	39,709 -2,733	-6%	-$502K	0.52%	41
2024 Q3	$8.38M	Sell	42,442 -6,003	-12%	-$1.12M	0.63%	32
2024 Q2	$8.31M	Sell	48,445 -1,550	-3%	-$257K	0.67%	33
2024 Q1	$9.1M	Buy	49,995 +6,433	+15%	+$1.11M	0.74%	30
2023 Q4	$6.75M	Sell	43,562 -73	-0.2%	-$10.6K	0.61%	40
2023 Q3	$6.5M	Sell	43,635 -1,349	-3%	-$198K	0.64%	37
2023 Q2	$6.06M	Sell	44,984 -5,702	-11%	-$836K	0.56%	45
2023 Q1	$8.08M	Sell	50,686 -8	-0%	-$1.22K	0.74%	28
2022 Q4	$8.19M	Sell	50,694 -109	-0.2%	-$16.7K	0.76%	30
2022 Q3	$6.82M	Sell	50,803 -898	-2%	-$129K	0.66%	35
2022 Q2	$7.92M	Buy	51,701 +2,621	+5%	+$401K	0.71%	36
2022 Q1	$7.96M	Sell	49,080 -5,392	-10%	-$783K	0.63%	40
2021 Q4	$7.38M	Sell	54,472 -950	-2%	-$112K	0.56%	45
2021 Q3	$5.98M	Buy	55,422 +1,185	+2%	+$135K	0.48%	53
2021 Q2	$6.11M	Buy	54,237 +2,275	+4%	+$256K	0.48%	59
2021 Q1	$5.62M	Buy	51,962 +4,059	+8%	+$434K	0.47%	56
2020 Q4	$5.13M	Sell	47,903 -6,397	-12%	-$615K	0.47%	53
2020 Q3	$4.76M	Buy	54,300 +6,502	+14%	+$612K	0.48%	51
2020 Q2	$4.69M	Buy	47,798 +3,089	+7%	+$272K	0.49%	49
2020 Q1	$3.41M	Buy	44,709 +1,050	+2%	+$89.4K	0.41%	59
2019 Q4	$3.87M	Buy	43,659 +2,250	+5%	+$187K	0.36%	62
2019 Q3	$3.14M	Sell	41,409 -180	-0.4%	-$12.3K	0.31%	69
2019 Q2	$3.02M	Sell	41,589 -830	-2%	-$65.2K	0.3%	72
2019 Q1	$3.42M	Sell	42,419 -580	-1%	-$47.4K	0.35%	65
2018 Q4	$3.96M	Buy	42,999 +3,300	+8%	+$290K	0.45%	52
2018 Q3	$3.75M	Sell	39,699 -1,596	-4%	-$151K	0.38%	59
2018 Q2	$3.83M	Sell	41,295 -3,419	-8%	-$334K	0.45%	52
2018 Q1	$4.23M	Buy	44,714 +764	+2%	+$83.9K	0.46%	52
2017 Q4	$4.25M	Sell	43,950 -3,585	-8%	-$338K	0.47%	53
2017 Q3	$4.22M	Sell	47,535 -2,564	-5%	-$195K	0.48%	53
2017 Q2	$3.63M	Sell	50,099 -550	-1%	-$37K	0.42%	55
2017 Q1	$3.3M	Buy	50,649 +10,724	+27%	+$674K	0.4%	60
2016 Q4	$2.5M	Sell	39,925 -756	-2%	-$46.1K	0.33%	74
2016 Q3	$2.56M	Buy	40,681 +756	+2%	+$48.9K	0.32%	81
2016 Q2	$2.47M	Sell	39,925 -5,064	-11%	-$309K	0.32%	77
2016 Q1	$2.57M	Buy	44,989 +9,519	+27%	+$531K	0.35%	65
2015 Q4	$2.1M	Sell	35,470 -250	-0.7%	-$14.4K	0.29%	77
2015 Q3	$1.94M	Sell	35,720 -1,430	-4%	-$93.1K	0.27%	83
2015 Q2	$2.5M	Buy	37,150 +120	+0.3%	+$7.83K	0.33%	68
2015 Q1	$2.17M	Sell	37,030 -3,380	-8%	-$204K	0.29%	77
2014 Q4	$2.64M	Sell	40,410 -5,516	-12%	-$348K	0.36%	65
2014 Q3	$2.65M	Sell	45,926 -956	-2%	-$53.1K	0.37%	63
2014 Q2	$2.65M	Sell	46,882 -6,450	-12%	-$338K	0.3%	66
2014 Q1	$2.74M	Buy	53,332 +75	+0.1%	+$3.79K	0.32%	57
2013 Q4	$2.81M	Sell	53,257 -1,568	-3%	-$77.1K	0.33%	59
2013 Q3	$2.45M	Buy	54,825 +11,800	+27%	+$523K	0.3%	64
2013 Q2	$1.78M	Buy	+43,025	New	+$1.88M	0.23%	85

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Trustmark National Bank Trust Department's ABBV Position: Q1 2026 in Review

Trustmark National Bank Trust Department increased its AbbVie (ABBV) stake by 0.34% in Q1 2026, buying an estimated $29.5K and bringing the position to 38,707 shares worth $8.42M. The position accounts for 0.54% of the portfolio, ranked #41.

Trustmark National Bank Trust Department first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $9.1M in Q1 2024. 4,087 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Trustmark National Bank Trust Department held 38,707 shares of AbbVie worth $8.42M as of Q1 2026.
Trustmark National Bank Trust Department bought 133 AbbVie shares in Q1 2026, an estimated $29.5K.
AbbVie made up 0.54% of Trustmark National Bank Trust Department's portfolio in Q1 2026, its #41 holding.
Trustmark National Bank Trust Department first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Trustmark National Bank Trust Department's AbbVie position peaked at $9.1M in Q1 2024.
4,087 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Trustmark National Bank Trust Department's 13F filing for Q1 2026, filed 14 May 2026.